Novo Nordisk A/S (Novo Nordisk) is a healthcare company engaged in discovery, development, manufacturing, and marketing of pharmaceutical products. The company’s business segments include diabetes and obesity care, and biopharmaceuticals.
Novo Nordisk addresses its direct impacts through a number of initiatives detailed in the company’s integrated annual report. The company prioritizes reducing the climate impacts of its operations through its ISO 14001 certified environmental management systems at all facilities; the company is also a member of the Pharmaceuticals Supply Chain Initiative and requires suppliers to monitor environmental impacts. In the long term, Novo Nordisk will be 100% powered by renewables by 2020. Separately, Novo Nordisk is leading the charge to improve access to diabetes treatments for underserved populations in developing nations, including differentiated pricing mechanisms and capacity building efforts to enhance local research and development capabilities. Notably, the company was able to provide low-cost insulin to numerous patients for only USD 0.15 per person per day. Tthe company also shows a strong commitment to anti-corruption as well, explicitly banning facilitation payments, requiring supplier compliance along its code of conduct, and adhering to several recognized codes and initiatives (e.g. PhRMA, UN Global Compact).
Despite the company’s ethics policies, Novo Nordisk faces continued false marketing accusations for several of its products.
Industry: Health Care
To the best of our knowledge the above information is accurate and was obtained from sources we believe to be reliable. Neither the information presented above nor any opinion expressed shall be construed as an offer to sell or a solicitation to buy the security. The views expressed are those of portfolio management as of 12/31/16 and may not reflect current opinions or subsequent events.